While clinical trials have demonstrated the efficacy of PI3K/Akt/mTOR inhibitors as monotherapy in endometrial cancer (Roncolato et al., 2019; Avila et al., 2022), as of 2024, the European Medicines Agency (EMA) has not granted approval for these inhibitors in endometrial cancer. This evidence concerns the gene AKT1 and endometrial cancer.